Page last updated: 2024-12-07
4-bromomethyl-3-nitrobenzoic acid
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
4-bromomethyl-3-nitrobenzoic acid: structure given in first source; a thiol photo-deprotection agent [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 132386 |
| CHEMBL ID | 1834878 |
| SCHEMBL ID | 40979 |
| SCHEMBL ID | 13801545 |
| MeSH ID | M0202584 |
Synonyms (29)
| Synonym |
|---|
| AC-6543 |
| bnba |
| 4-(bromomethyl)-3-nitrobenzoic acid |
| AG-205/15424370 |
| EU-0050907 |
| 4-bromomethyl-3-nitrobenzoic acid, 97% |
| 55715-03-2 |
| A8043 |
| CHEMBL1834878 |
| 4-bromomethyl-3-nitrobenzoic acid |
| benzoic acid, 4-(bromomethyl)-3-nitro- |
| 4-(bromomethyl)-3-nitrobenzoicacid |
| AKOS005175066 |
| FT-0640332 |
| AM808253 |
| SCHEMBL40979 |
| QMAHVAFURJBOFV-UHFFFAOYSA-N |
| 3-nitro-4-bromomethylbenzoic acid |
| 4-bromomethyl-3-nitro benzoic acid |
| 4-bromomethyl-3-nitro-benzoic acid |
| 3-nitro-4-bromomethyl benzoic acid |
| ortho-nitro alpha-bromo-p-toluic acid |
| SCHEMBL13801545 |
| W-203101 |
| DTXSID30204251 |
| mfcd00216575 |
| AMY23991 |
| STR05282 |
| SY034741 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (5)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID623723 | Antiparasitic activity against promastigote form of Leishmania amazonensis IFLA/BR/67/PH8 after 48 hrs by MTT assay | 2011 | European journal of medicinal chemistry, Nov, Volume: 46, Issue:11 | Synthesis and evaluation of the anti parasitic activity of aromatic nitro compounds. |
| AID623724 | Inhibition of cell proliferation of phytohemagglutinin-induced human PBMC | 2011 | European journal of medicinal chemistry, Nov, Volume: 46, Issue:11 | Synthesis and evaluation of the anti parasitic activity of aromatic nitro compounds. |
| AID623725 | Selectivity index, ratio of IC50 for human PBMC to IC50 for Leishmania amazonensis IFLA/BR/67/PH8 | 2011 | European journal of medicinal chemistry, Nov, Volume: 46, Issue:11 | Synthesis and evaluation of the anti parasitic activity of aromatic nitro compounds. |
| AID623722 | Trypanocidal activity against intracellular trypomastigote form of Trypanosoma cruzi Tulahuen expressing beta-galactosidase infected in mouse L929 cells after 7 days by microplate reader analysis | 2011 | European journal of medicinal chemistry, Nov, Volume: 46, Issue:11 | Synthesis and evaluation of the anti parasitic activity of aromatic nitro compounds. |
| AID623721 | Trypanocidal activity against intracellular amastigote form of Trypanosoma cruzi Tulahuen expressing beta-galactosidase infected in mouse L929 cells after 7 days by microplate reader analysis | 2011 | European journal of medicinal chemistry, Nov, Volume: 46, Issue:11 | Synthesis and evaluation of the anti parasitic activity of aromatic nitro compounds. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (6)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 22.29
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (22.29) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||